Microcap Ledger Sutro Biopharma, Inc. $STRO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Fiscal year end
- December 31
- Shares outstanding
- 16,581,171 [10-Q 2026-08-12]
What the company doesAI summary of filing
Sutro Biopharma is a clinical-stage oncology company that develops antibody-drug conjugates (ADCs) and next-generation ADC modalities enabled by its proprietary XpressCF® and XpressCF+® cell-free protein synthesis platforms. The company's lead program, STRO-004, is a tissue factor-targeting ADC currently in Phase 1 clinical trials for solid tumors; preclinical candidates include STRO-006 (integrin alpha v beta 6-targeting ADC) and STRO-227 (dual-payload PTK7-targeting ADC). Sutro generates revenue through research and development collaborations with pharmaceutical partners including Astellas, Merck, Celgene/BMS, and EMD Serono, having received approximately $1.016 billion in aggregate payments through December 2025, though the company is pre-revenue regarding its own product candidates. [10-K 2026-03-23]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $24.36M | −$77.02M | −$80.55M | $54.34M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $102.48M | −$191.00M | −$177.23M | $58.13M | [10-K 2026-03-23] |
| FY ended Dec 2024 | $62.04M | −$227.00M | −$191.54M | $190.30M | [10-K 2026-03-23] |
- Quarterly cash burn
- −$40.27M
- Cash runway Estimate
- ~4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 82,458,725 | [10-Q 2024-11-13] |
| 2025-03-06 | 83,775,336 | [10-K 2025-03-13] |
| 2025-05-02 | 84,461,365 | [10-Q 2025-05-08] |
| 2025-08-01 | 84,774,177 | [10-Q 2025-08-07] |
| 2025-10-31 | 85,135,290 | [10-Q 2025-11-06] |
| 2026-03-16 | 16,567,238 | [10-K 2026-03-23] |
| 2026-05-08 | 16,570,439 | [10-Q 2026-05-14] |
| 2026-08-07 | 16,581,171 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2026-03-23; declared effective 2026-04-01 [S-3 2026-03-23]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-06-25. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-06-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-25] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-18 | Gerber Hans-Peter | exercise | 3,750 | — | [4 2026-09-22] |
| 2026-09-18 | Gerber Hans-Peter | other | 1,345 | $15.34 | [4 2026-09-22] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-07-30 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-08 | 8-K | Shareholder vote results |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 10-Q | Quarterly report |
| 2026-05-14 | 8-K | Results of operations |
| 2026-05-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-01 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $STRO
Email me when Sutro Biopharma, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.